

Ramachandran Murali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6407490/publications.pdf>

Version: 2024-02-01

124
papers

4,975
citations

94433

37
h-index

102487

66
g-index

126
all docs

126
docs citations

126
times ranked

7120
citing authors

#	ARTICLE	IF	CITATIONS
1	ErbB receptors: from oncogenes to targeted cancer therapies. <i>Journal of Clinical Investigation</i> , 2007, 117, 2051-2058.	8.2	478
2	Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. <i>Nature Communications</i> , 2015, 6, 7158.	12.8	264
3	Polymersomes: A new multi-functional tool for cancer diagnosis and therapy. <i>Methods</i> , 2008, 46, 25-32.	3.8	191
4	Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. <i>Nature Biotechnology</i> , 2000, 18, 194-198.	17.5	175
5	HER2/Neu: mechanisms of dimerization/oligomerization. <i>Oncogene</i> , 2000, 19, 6093-6101.	5.9	144
6	Role of tryptophan repeats and flanking amino acids in Myb-DNA interactions.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 8452-8456.	7.1	135
7	The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2.9 Å Resolution. <i>Journal of Molecular Biology</i> , 1994, 242, 430-455.	4.2	133
8	Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6. <i>Gastroenterology</i> , 2017, 152, 1477-1491.	1.3	133
9	A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. <i>Journal of Clinical Investigation</i> , 2006, 116, 1525-1534.	8.2	122
10	Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF binding to its receptor. <i>Nature Biotechnology</i> , 1997, 15, 1266-1270.	17.5	118
11	Structure of Sad1-UNC84 Homology (SUN) Domain Defines Features of Molecular Bridge in Nuclear Envelope. <i>Journal of Biological Chemistry</i> , 2012, 287, 5317-5326.	3.4	114
12	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. <i>Nature Medicine</i> , 2018, 24, 1887-1898.	30.7	113
13	iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates. <i>Nature Medicine</i> , 2020, 26, 289-299.	30.7	102
14	Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy.. <i>Journal of Experimental Medicine</i> , 1996, 183, 829-836.	8.5	99
15	Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies: A Structure-Function Analysis. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2565-2574.	6.4	99
16	Disabling of Receptor Activator of Nuclear Factor- κ B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo. <i>Journal of Biological Chemistry</i> , 2004, 279, 8269-8277.	3.4	83
17	Therapeutic peptides and peptidomimetics. <i>Current Opinion in Biotechnology</i> , 1997, 8, 435-441.	6.6	82
18	Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics. <i>Journal of Biological Chemistry</i> , 2002, 277, 28330-28339.	3.4	82

#	ARTICLE	IF	CITATIONS
19	An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma. <i>Cancer Research</i> , 2007, 67, 202-208.	0.9	80
20	Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 3794-3798.	7.1	76
21	Mitochondrial protein BmPAPI modulates the length of mature piRNAs. <i>Rna</i> , 2013, 19, 1405-1418.	3.5	75
22	Group B Streptococcus Evades Host Immunity by Degrading Hyaluronan. <i>Cell Host and Microbe</i> , 2015, 18, 694-704.	11.0	66
23	c-Rel is a myeloid checkpoint for cancer immunotherapy. <i>Nature Cancer</i> , 2020, 1, 507-517.	13.2	63
24	An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. <i>Gastroenterology</i> , 2018, 155, 1985-1998.e5.	1.3	61
25	Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. <i>Hepatology</i> , 2018, 68, 1726-1740.	7.3	55
26	Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. <i>Oncogene</i> , 1998, 16, 1197-1207.	5.9	52
27	The Centrosome in Normal and Transformed Cells. <i>DNA and Cell Biology</i> , 2004, 23, 475-489.	1.9	51
28	Direct Antimicrobial Activity of IFN- γ . <i>Journal of Immunology</i> , 2017, 198, 4036-4045.	0.8	48
29	Structural basis for ligand-mediated mouse GITR activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 641-645.	7.1	45
30	Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5465-5470.	7.1	45
31	Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. <i>Nature Biotechnology</i> , 1997, 15, 150-154.	17.5	44
32	Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 6252-6257.	7.1	43
33	Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. <i>Nature Biotechnology</i> , 1996, 14, 472-475.	17.5	42
34	Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185her2/neu Monoclonal Antibodies. <i>Experimental and Molecular Pathology</i> , 1999, 67, 15-25.	2.1	42
35	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1341-1354.	4.1	41
36	The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside. <i>Journal of Structural Biology</i> , 1997, 119, 6-16.	2.8	40

#	ARTICLE	IF	CITATIONS
37	Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. <i>Frontiers in Physiology</i> , 2014, 5, 478.	2.8	40
38	Transduction of Activation Signal That Follows HIV-1 Binding to CD4 and CD4 Dimerization Involves the Immunoglobulin CDR3-like Region in Domain 1 of CD4. <i>Journal of Biological Chemistry</i> , 1997, 272, 19441-19450.	3.4	39
39	Functional Role of Residues Corresponding to Helical Domain II (Amino Acids 35 to 46) of Human Immunodeficiency Virus Type 1 Vpr. <i>Journal of Virology</i> , 2000, 74, 10650-10657.	3.4	37
40	Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. <i>Oncogene</i> , 2012, 31, 1938-1948.	5.9	37
41	Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. <i>Vaccine</i> , 2007, 25, 3022-3031.	3.8	36
42	The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. <i>Arthritis Research and Therapy</i> , 2015, 17, 251.	3.5	36
43	HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 631-639.	3.3	36
44	Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10970-10975.	7.1	35
45	Mitochondrial NDUFS3 regulates the ROS-mediated onset of metabolic switch in transformed cells. <i>Biology Open</i> , 2013, 2, 295-305.	1.2	35
46	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. <i>PLoS ONE</i> , 2017, 12, e0171356.	2.5	33
47	Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6599-6604.	7.1	30
48	The TNF Receptor Superfamily: Role in Immune Inflammation and Bone Formation. <i>Immunologic Research</i> , 2003, 27, 287-294.	2.9	29
49	Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: The Fab is directed against an intermediate in the helix-coil dynamics of the enzyme. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 12562-12567.	7.1	28
50	HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand. <i>DNA and Cell Biology</i> , 2005, 24, 351-358.	1.9	28
51	Fn14-TRAIL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis. <i>American Journal of Pathology</i> , 2009, 174, 460-474.	3.8	28
52	The promise of the anti-idiotypic concept. <i>Frontiers in Oncology</i> , 2012, 2, 196.	2.8	28
53	Molecular recognition of the Lewis Y antigen by monoclonal antibodies. <i>Protein Engineering, Design and Selection</i> , 1996, 9, 447-459.	2.1	27
54	Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System. <i>Mini-Reviews in Medicinal Chemistry</i> , 2001, 1, 5-16.	2.4	27

#	ARTICLE	IF	CITATIONS
55	Structural Studies of Synthetic Peptide Fragments Derived from the HIV-1 Vpr Protein. <i>Biochemical and Biophysical Research Communications</i> , 1998, 244, 732-736.	2.1	26
56	AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. <i>Oncogene</i> , 2006, 25, 7740-7746.	5.9	26
57	Targeting erbB receptors. <i>Seminars in Cell and Developmental Biology</i> , 2010, 21, 961-966.	5.0	26
58	SSTR2-Based Reporters for Assessing Gene Transfer into Nonâ€‘Small Cell Lung Cancer: Evaluation Using an Intrathoracic Mouse Model. <i>Human Gene Therapy</i> , 2011, 22, 55-64.	2.7	26
59	Crystallization and Preliminary X-ray Analysis of Human Î±-Galactosidase A Complex. <i>Journal of Molecular Biology</i> , 1994, 239, 578-580.	4.2	25
60	Peptide drugs accelerate BMPâ€‘2â€‘induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling. <i>BioEssays</i> , 2016, 38, 717-725.	2.5	25
61	Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. <i>Oncogene</i> , 1998, 16, 2835-2842.	5.9	24
62	Structure-based design of immunologically active therapeutic peptides. <i>Immunologic Research</i> , 1998, 17, 163-169.	2.9	24
63	Epitope-Tagging Approach to Determine the Stoichiometry of the Structural and Nonstructural Proteins in the Virus Particles: Amount of Vpr in Relation to Gag in HIV-1. <i>Virology</i> , 2000, 268, 364-371.	2.4	24
64	Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses. <i>Frontiers in Immunology</i> , 2014, 5, 308.	4.8	23
65	Effect of Mutagenesis of GPIIb Amino Acid 273 on the Expression and Conformation of the Platelet Integrin GPIIb-IIIaâ€‘. <i>Biochemistry</i> , 1996, 35, 14304-14311.	2.5	22
66	Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody. <i>Journal of Molecular Recognition</i> , 1997, 10, 269-276.	2.1	22
67	Structure Based Antibody-Like Peptidomimetics. <i>Pharmaceuticals</i> , 2012, 5, 209-235.	3.8	21
68	Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points. <i>EMBO Journal</i> , 2001, 20, 2394-2403.	7.8	19
69	Crystal Structure of a TSH Receptor Monoclonal Antibody: Insight Into Graves' Disease Pathogenesis. <i>Molecular Endocrinology</i> , 2015, 29, 99-107.	3.7	19
70	Delivery of RANKL-Binding Peptide OP3-4 Promotes BMP-2â€‘Induced Maxillary Bone Regeneration. <i>Journal of Dental Research</i> , 2016, 95, 665-672.	5.2	19
71	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. <i>Nature Communications</i> , 2022, 13, 669.	12.8	19
72	Molecular Structure, Conformational Analysis, and Structureâ€‘Activity Studies of Dendrotoxin and Its Homologues Using Molecular Mechanics and Molecular Dynamics Techniques. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2141-2155.	6.4	18

#	ARTICLE	IF	CITATIONS
73	Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions. <i>Journal of General Virology</i> , 2014, 95, 700-711.	2.9	17
74	Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage. <i>PLoS ONE</i> , 2018, 13, e0200714.	2.5	16
75	The induction of RANKL molecule clustering could stimulate early osteoblast differentiation. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 435-440.	2.1	16
76	Asporin, an extracellular matrix protein, is a beneficial regulator of cardiac remodeling. <i>Matrix Biology</i> , 2022, 110, 40-59.	3.6	16
77	HIV-1 Vpr: Genetic Diversity and Functional Features from the Perspective of Structure. <i>DNA and Cell Biology</i> , 2004, 23, 207-222.	1.9	14
78	Peptide-induced de novo bone formation after tooth extraction prevents alveolar bone loss in a murine tooth extraction model. <i>European Journal of Pharmacology</i> , 2016, 782, 89-97.	3.5	13
79	TNF α Inhibition in MRL/lpr Mice Ameliorates Pulmonary but not Renal Disease. <i>Journal of Autoimmunity</i> , 2002, 19, 215-222.	6.5	12
80	Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. <i>Gynecologic Oncology</i> , 2020, 159, 277-284.	1.4	12
81	Structural studies on an inhibitory antibody against <i>Thermus aquaticus</i> DNA polymerase suggest mode of inhibition. <i>Protein Engineering, Design and Selection</i> , 1998, 11, 79-86.	2.1	11
82	Structure of Taq DNA polymerase shows a new orientation for the structure-specific nuclease domain. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1999, 55, 1971-1977.	2.5	11
83	Basal Protein Expression Is Associated With Worse Outcome and Trastuzumab Resistance in HER2+ Invasive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 448-457.e2.	2.4	11
84	A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes. <i>Virology Journal</i> , 2008, 5, 99.	3.4	10
85	Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF- κ B-Activation. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 1-11.	1.6	10
86	The intra-articular injection of RANKL-binding peptides inhibits cartilage degeneration in a murine model of osteoarthritis. <i>Journal of Pharmacological Sciences</i> , 2017, 134, 124-130.	2.5	10
87	Structure of Taq DNA polymerase shows a new orientation for the structure-specific nuclease domain. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1999, 55, 1971-1977.	2.5	10
88	Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. <i>FEBS Letters</i> , 2000, 469, 191-195.	2.8	9
89	Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. <i>Experimental and Molecular Pathology</i> , 2013, 94, 372-379.	2.1	9
90	Structure and conformation of linear peptides. IX. Structure of l-tyrosyl-l-phenylalanine. <i>International Journal of Peptide and Protein Research</i> , 2009, 29, 187-192.	0.1	8

#	ARTICLE	IF	CITATIONS
91	A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model. <i>European Journal of Pharmacology</i> , 2012, 679, 132-138.	3.5	8
92	Probing Structural Variability at the N Terminus of the TSH Receptor with a Murine Monoclonal Antibody That Distinguishes between Two Receptor Conformational Forms. <i>Endocrinology</i> , 2013, 154, 562-571.	2.8	8
93	The hidden code in genomics: a tool for gene discovery. <i>Journal of Molecular Recognition</i> , 2001, 14, 269-272.	2.1	7
94	Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2550-2553.	2.2	7
95	Characterization of Mouse tGolgin-1 (Golgin-245/trans-Golgi p230/256 kD Golgin) and Its Upregulation during Oligodendrocyte Development. <i>DNA and Cell Biology</i> , 2002, 21, 505-517.	1.9	6
96	Cloning and characterization of rhesus IL-18 binding protein, a natural antagonist to IL-18. <i>Cytokine</i> , 2010, 51, 232-239.	3.2	6
97	Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress. <i>Molecular Cancer Research</i> , 2021, 19, 1375-1388.	3.4	6
98	Defining the Recognition Elements of Lewis Y-Reactive Antibodies. <i>PLoS ONE</i> , 2014, 9, e104208.	2.5	6
99	Study of Disabling T-Cell Activation and Inhibiting T-Cell-Mediated Immunopathology Reveals a Possible Inverse Agonist Activity of CD4 Peptidomimetics. <i>Experimental and Molecular Pathology</i> , 2002, 73, 93-103.	2.1	5
100	Structure and conformation of linear peptides. <i>International Journal of Peptide and Protein Research</i> , 1986, 27, 478-482.	0.1	5
101	Structure and conformation of linear peptides. X. Structure of glycyl-L-phenylalanine hydrochloride. <i>International Journal of Peptide and Protein Research</i> , 1987, 29, 374-380.	0.1	5
102	New perspectives on anti-HER2/neu therapeutics. <i>Drug News and Perspectives</i> , 2000, 13, 325-9.	1.5	5
103	Structure-Based Approaches to Inhibition of erbB Receptors with Peptide Mimetics. <i>Immunologic Research</i> , 2003, 27, 303-308.	2.9	4
104	Structure-Based Peptide Mimicry of Tumor-Associated Antigens. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2013, 32, 1-5.	1.6	4
105	The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2015, 34, 295-302.	1.6	4
106	The Effects of Receptor Activator of NF- κ B Ligand-Binding Peptides on Bone Resorption and Bone Formation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 648084.	3.7	4
107	Disabling the Nuclear Translocation of RelA/NF- κ B by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 419-430.	1.8	4
108	The Synthetic CD4 Exocyclic CDR3. AME(82-89) Inhibits NF- κ B Nuclear Translocation, HIV-1 Promoter Activation, and Viral Gene Expression. <i>DNA and Cell Biology</i> , 1999, 18, 819-828.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Deoxycholate-Based Method to Screen Phage Display Clones for Uninterrupted Open Reading Frames. BioTechniques, 2002, 33, 294-296.	1.8	3
110	Antibody like peptidomimetics as large scale immunodetection probes. Cellular and Molecular Biology, 2003, 49, 209-16.	0.9	3
111	Preliminary crystallographic data for an Fab to the melanoma-associated GD2 ganglioside, and the purification of a soluble form of this antigen. Acta Crystallographica Section D: Biological Crystallography, 1995, 51, 124-126.	2.5	2
112	Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity. Thyroid, 2018, 28, 933-940.	4.5	2
113	Perspective on Crystallographic Studies of Antibody Structures. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2020, 39, 195-198.	1.6	1
114	Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics. Breast Cancer: Targets and Therapy, 2021, Volume 13, 575-593.	1.8	1
115	Should All Memory B Cells Recruited to the Germinal Center Be Antigen Specific?. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 50-51.	1.6	0
116	Rational Design of Constrained Peptides as Protein Interface Inhibitors. Antibodies, 2021, 10, 32.	2.5	0
117	Design And Development Of Small-molecule Inhibitor Of Tumor Necrosis Factor-. , 2000, , .		0
118	Anti-HER2/Neu Peptide Mimetic. , 2011, , 210-213.		0
119	Carbohydrate Mimetic Peptide Vaccines. , 2012, , 229-254.		0
120	Anti-Her2/Neu Peptide Mimetic. , 2015, , 1-4.		0
121	Anti-Her2/Neu Peptide Mimetic. , 2015, , 279-283.		0
122	Anti-Her2/Neu Peptide Mimetic. , 2017, , 1-4.		0
123	Structure based design and characterization of exocyclic peptidomimetics that inhibit TNF± binding to its receptor. , 1999, , 61-63.		0
124	Co-Variation of Serum Osteoprotegerin and Pigment-Epithelial Derived Factor as Biomarker of Pancreatic Cancer.. Austin Journal of Gastroenterology, 2022, 9, .	0.0	0